Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Afatinib Dimaleate in Treating Patients With Advanced Refractory Urothelial Cancer

NCT02122172 is registered in ClinicalTrials.gov with University of Chicago as lead sponsor.

NCT NCT02122172
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02122172 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Afatinib Dimaleate in Treating Patients With Advanced Refractory Urothelial Cancer
Lead sponsor
University of Chicago
Phase
Phase 2
Overall status
Terminated
Start date
September 13, 2017
Completion date
April 4, 2024
Enrollment
32 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

distal urethral cancer, proximal urethral cancer, recurrent bladder cancer, recurrent urethral cancer, stage iii bladder cancer, stage iii urethral cancer, stage iv bladder cancer, stage iv urethral cancer, ureter cancer